HOME >> BIOLOGY >> NEWS
Could plain soap and probiotics beat hospital bugs?

Doctors might be better off washing their hands with yoghurt instead of relying on antiseptic soap-scrubbing, according to a new discussion paper by a UCL (University College London) researcher.

Scientists should investigate whether saturating the skin with 'good' bacteria would offer better protection against deadly germs, says the paper. Professor Mark Spigelman, of the UCL Centre for Infectious Diseases and International Health, is calling for a study to be set up in hospital units in which antibiotics would be banned, to explore alternative health protection measures against MRSA.

In the paper, published in the November issue of Annals of the Royal College of Surgeons, Professor Spigelman says the time has come to re-evaluate the concept of using antibiotics and scrubbing hands and wounds with antiseptic soaps. His paper outlines a six-point proposal to set up surgical hospitals which would be antibiotic-free and would instead comply with the novel standard practices being investigated.

Professor Mark Spigelman says: "Inappropriate use of antibiotics remains a major problem, despite our ever-growing understanding of how bacteria behave. For example, any student who has grown bacteria in a lab will know that they generally do not grow on top of one another. So when we wash our hands, we could actually be killing off harmless commensals to the extent that we leave space for other bacteria, such as MRSA strains, to settle.

"Perhaps we should be thinking about using probiotics and even dipping our hands after thorough washing into a solution which contains harmless bacteria, which could then colonise our skin and prevent pathogenic bacteria from settling on it.

"It must be remembered that after almost 40 years, MRSA has not become widespread except in hospitals where we use the most advanced antibiotics and most rigorous antiseptic measures. Why is this? More of the same does not seem to be working new antibiotics and anti
'"/>

Contact: Judith H Moore
judith.moore@ucl.ac.uk
44-207-679-7678
University College London
31-Oct-2005


Page: 1 2

Related biology news :

1. Could fungal collection hold the key to new life-saving drugs?
2. Could USA presidential DNA trail reveal Middle-Eastern origins?
3. Could estriol be the elixir for MS?
4. Quantum dots reviewed -- Could these nanoparticles hold the cure to cancer?
5. Could a pint of cider help keep the doctor away?
6. Friend or foe: Could a protein linked to Alzheimers be related to vision loss in seniors?
7. Could better mangrove habitats have spared lives in the 2004 tsunami?
8. Recurrent miscarriages: Could prednisolone reduce the occurrence of this distressing condition?
9. Could microbes solve Russias chemical weapons conundrum?
10. Could schizophrenia arise from a single defect?
11. X-ray images help explain limits to insect body size

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Could plain soap and probiotics beat hospital bugs

(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
(Date:7/7/2015)... -- Research and Markets ( ... "Capacitive Fingerprint Sensors Patent Landscape" report ... fingerprint sensing technology is the most reliable and ... developed. This patent landscape focuses on fingerprint sensors ... of capacitive fingerprint sensors is closely linked to ...
(Date:7/7/2015)... 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... mobile commerce market announces a revised version of one of its ... will air on CNBC in New York , ... and San Francisco metro areas.    ... Wocket,s ability to replace all the cards in your wallet and ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
(Date:7/29/2015)... , ... July 29, 2015 , ... The third Medical ... combination products , in particular, drug/device combinations. The current system received a score ... Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... it has selected an optimized Erk inhibitor molecule ... the development of a new class of potential ... represents a prime target for therapeutic intervention in ... and survival benefits for B-Raf and Mek inhibitors. ...
(Date:7/29/2015)... ... July 29, 2015 , ... CSSi ... Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences is specialized in ... core expertise of PRC Clinical is focused on Clinical Trial Management, Clinical Site ...
(Date:7/29/2015)... TX (PRWEB) , ... July 29, 2015 , ... Costello ... new levee system to protect the Orange County, Texas area from future storm ... multi-firm design team in determining several potential levee alignment alternatives for providing protection, Costello ...
Breaking Biology Technology:Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Preventing Storm Surge Flooding in Houston 2
Cached News: